Epirubicin-Kimia

Product Description
EXAMON Handelsges.m.b.H.

-
AT
-
2024On CPHI since
Categories
Specifications
EXAMON Handelsges.m.b.H.

-
AT
-
2024On CPHI since
More Products from EXAMON Handelsges.m.b.H. (32)
-
Product Bortezomib-Kimia
• Inhibits the 26S proteasome, triggering targeted tumor cell apoptosis. • Clinically indicated for multiple myeloma and mantle cell lymphoma. • Offers flexible IV and subcutaneous administration options. • Demonstrated improvements in survival and quality of life. • Established, well-characterized sa... -
Product Calcium folinate (levoleucovorin)-Kimia
• Supports DNA synthesis and repair while mitigating methotrexate toxicity. • Proven efficacy in enhancing fluorouracil therapy for colorectal cancer and serving as methotrexate rescue. • Enhances chemotherapeutic regimens to optimize patient outcomes. • Demonstrated tolerability and manageable adverse... -
Product Carboplatin-Kimia
• Disrupts tumor DNA through crosslink formation to impede cell replication. • Widely validated in the treatment of various solid malignancies, including ovarian and lung cancers. • Administered via infusion to integrate seamlessly into contemporary oncology protocols. • Exhibits manageable adverse eff... -
Product Cisplatin-Kimia
• Facilitates DNA crosslinking to inhibit replication and promote cancer cell apoptosis. • Demonstrates robust efficacy in various solid tumors, including testicular, ovarian, and bladder cancers. • Delivered via infusion, aligning with established oncology treatment protocols. • Often paired with othe... -
Product Docetaxel-Kimia
• A potent taxane agent which stabilizes microtubules to disrupt cell division and promote apoptosis in malignant cells. • Demonstrated efficacy across various cancers including breast, lung, and prostate. • Seamlessly integrated into standard oncology treatment protocols. • Adverse effects are managea... -
Product Doxorubicin-Kimia
• An anthracycline mechanism which intercalates into DNA and inhibits topoisomerase II, promoting the generation of free radicals that induce tumor cell death. • Demonstrates a longstanding, evidence-based role in treating breast cancer, lymphomas, sarcomas, and other malignancies. • Delivered via IV in... -
Product Gemcitabine-Kimia
• Gemcitabine functions as a nucleoside analog that, once activated, impedes DNA synthesis and triggers tumor cell death. • Its therapeutic use is well-established in treating a range of malignancies, including pancreatic, lung, and breast cancers. • The drug is administered through intravenous infusion... -
Product Irinotecan-Kimia
• Inhibits topoisomerase I to interfere with DNA replication and trigger tumor cell apoptosis. • Clinically validated through extensive studies in metastatic colorectal and other solid tumors. • Delivered via intravenous infusion to integrate seamlessly with established chemotherapy regimens. • Demonst... -
Product Methotrexate-Kimia
• Inhibits dihydrofolate reductase to block folate metabolism and impede DNA synthesis. • Provides rapid therapeutic effects through intravenous, intramuscular, intra-arterial injection. • Widely used in oncology and autoimmune therapies to manage various conditions. • Proven to induce remission a... -
Product Oxaliplatin-Kimia
• Platinum-based compound that forms DNA cross-links to disrupt cancer cell replication. • Clinically proven in colorectal and gastrointestinal malignancies through robust trials. • Administered via intravenous infusion, fitting into established chemotherapy regimens such as FOLFOX. • Clinical studies ... -
Product Paclitaxel-Kimia
• Stabilizes microtubules to obstruct cell division by preventing spindle disassembly. • Supported by extensive clinical evidence in treating breast, ovarian, lung, and other solid tumors. • Administered via intravenous infusion, integrating well with established chemotherapy regimens. -
Product Fluorouracil-Kimia
• Fluorouracil disrupts DNA synthesis by inhibiting thymidylate synthase, impairing tumor cell proliferation. • Proven efficacy across multiple cancers, including colorectal and breast malignancies, through comprehensive clinical studies. • Primarily administered via intravenous infusion. • Demonstrate...
Frequently Viewed Together
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance